- Home
- BCDA vs FTEL Comparison
BCDA vs FTEL Comparison
Compare BCDA & FTEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCDA
- FTEL
- Stock Information
- Founded
- BCDA N/A
- FTEL 2007
- Country
- BCDA United States
- FTEL Australia
- Employees
- BCDA N/A
- FTEL N/A
- Industry
- BCDA Biotechnology: Pharmaceutical Preparations
- FTEL
- Sector
- BCDA Health Care
- FTEL
- Exchange
- BCDA Nasdaq
- FTEL Nasdaq
- Market Cap
- BCDA 11.0M
- FTEL 11.1M
- IPO Year
- BCDA N/A
- FTEL 2023
- Fundamental
- Price
- BCDA $2.15
- FTEL $0.51
- Analyst Decision
- BCDA Strong Buy
- FTEL
- Analyst Count
- BCDA 1
- FTEL 0
- Target Price
- BCDA $25.00
- FTEL N/A
- AVG Volume (30 Days)
- BCDA 52.3K
- FTEL 222.3K
- Earning Date
- BCDA 08-12-2025
- FTEL 07-07-2025
- Dividend Yield
- BCDA N/A
- FTEL N/A
- EPS Growth
- BCDA N/A
- FTEL N/A
- EPS
- BCDA N/A
- FTEL N/A
- Revenue
- BCDA $3,000.00
- FTEL $4,990,695.00
- Revenue This Year
- BCDA N/A
- FTEL N/A
- Revenue Next Year
- BCDA N/A
- FTEL N/A
- P/E Ratio
- BCDA N/A
- FTEL N/A
- Revenue Growth
- BCDA N/A
- FTEL 29.02
- 52 Week Low
- BCDA $1.63
- FTEL $0.36
- 52 Week High
- BCDA $4.66
- FTEL $49.50
- Technical
- Relative Strength Index (RSI)
- BCDA 51.13
- FTEL 42.43
- Support Level
- BCDA $1.98
- FTEL $0.36
- Resistance Level
- BCDA $2.45
- FTEL $0.50
- Average True Range (ATR)
- BCDA 0.17
- FTEL 0.05
- MACD
- BCDA 0.01
- FTEL 0.00
- Stochastic Oscillator
- BCDA 53.19
- FTEL 49.08
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
About FTEL Fitell Corporation
Fitell Corp engages in primary operations of selling gym and fitness equipment in Australia through its indirectly held wholly owned subsidiaries. It operates in two segments: online fitness equipment distribution and licensing business to service the large and growing boutique fitness sector of the broader health and fitness club industry. The majority fitness equipment business is conducted in Australia via its own e-commerce platform and, through third-party sites. Licensing service offers a turnkey solution for personal training studios and commercial gym chains. The company earns maximum of revenue for retail.